Crucell corporate brochure (PDF)

More documents

Recommendations

Info

28 Our business – Products Our broad range of innovative products Vaccines play a vital role in protecting against disease and have contributed significantly to the improvement of global public health. Smallpox was eradicated through the use of vaccines. Significant advances include the introduction of combination vaccines and the development of new vaccine technologies. In 2010, a Crucell vaccine was given to 190 people every minute. 1 Over the full year, more than 105 million doses of vaccines were distributed in more than 100 countries, thereby preventing more than 3.6 million cases of infectious diseases and over 809, 000 deaths that would otherwise have occurred. 1 Figures based on Crucell’s top 5 vaccines Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif® and Inflexal® V. Total 101,666,000 doses minus 2% waste (2,033,320 doses) = 99,632,680 doses sold in 2010 / 525600 minutes in 2010 = 189.5598 doses administered per minute. www.crucell.com In this section, you will find information about Crucell’s marketed products and comprehensive information about the diseases each of these vaccines is designed to prevent. Quinvaxem® Quinvaxem® fully liquid pentavalent (five-in-one) vaccine protects infants against five deadly childhood infections: diphtheria (D), tetanus (T), pertussis (P, whooping cough), hepatitis B (HepB), and Haemophilus influenzae type b (Hib). Combination vaccines help to simplify and harmonize vaccination schedules, leading to increased vaccine coverage and greater costeffectiveness. As the first fully liquid pentavalent DTwP–HepB–Hib vaccine brought to the market, Quinvaxem® further simplified vaccine delivery because it is ready to use as soon as the vial is opened. This makes it an ideal choice for protecting babies in developing countries with infrastructure and hygiene problems. Quinvaxem® remains the only fully liquid pentavalent vaccine that offers these advantages in a preservative-free formulation. Since the launch of Quinvaxem® in 2006, over 200 million doses of this life-saving vaccine have been delivered to developing countries, including 50 GAVI-supported countries. Most were low-income countries supplied through Unicef and the Pan American Health Organization (PAHO). With this innovation, Crucell has become a major partner in protecting children in under-resourced countries.
Our business – Products Cases of disease prevented by Quinvaxem® < 5,000 5,000–10,000 10,000–100,000 > 100,000 No report Hepavax-Gene® Hepavax-Gene® is a recombinant vaccine against hepatitis B virus infection, providing long-term protection. With a track record of more than 800 million doses administered worldwide since the launch of this vaccine in 1997, it is also one of the established WHO pre-qualified vaccines. 190 people Were given a Crucell vaccine every minute during 2010. 105+ mln Doses of vaccines were distributed in more than 100 countries in 2010. 3.6 mln Cases of infectious diseases were prevented in 2010. 29
Page 1 and 2: Bringing innovation to global healt
Page 3 and 4: 2010 key highlights Revenues and ot
Page 5 and 6: Overview - Crucell at a glance Cruc
Page 7 and 8: Overview - Crucell at a glance broa
Page 9 and 10: Overview - Crucell: A global perspe
Page 11 and 12: Overview - Message from our CEO and
Page 13 and 14: Our business - Research and develop
Page 23 and 24: Our business - Technologies Crucell
Page 25 and 26: Our business - Technologies PER.C6
Page 27 and 28: Our business - Technologies MAbstra
Page 29: Our business - Products Crucell foc
Page 33 and 34: Our business - Products areas as we
Page 35 and 36: Crucell’s commitment to the world
Page 77: Crucell’s commitment to the world
Page 80:
www.crucell.com Newtonweg 1 2333 CP
show all

Crucell corporate brochure (PDF)

Create successful ePaper yourself

Delete template?

Save as template?